The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world’s best-selling multiple sclerosis treatment. Justices heard arguments Wednesday in a case that threatens to cut into the profits of Israel-based Teva Pharmaceutical Industries Ltd., which sells $4 billion-a-year worth of the drug known as Copaxone.